Aprea Therapeutics
APRE
22 hedge funds and large institutions have $1.71M invested in Aprea Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
18% more capital invested
Capital invested by funds: $1.45M → $1.71M (+$266K)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding
Funds holding: 22 → 22 (0)
4.65% less ownership
Funds ownership: 24.24% → 19.6% (-4.6%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$507K |
| 2 |
VPC
Vestal Point Capital
New York
|
+$275K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.5K |
| 4 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
+$47.4K |
| 5 |
Renaissance Technologies
New York
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$290K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$103K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$43.5K |
| 4 |
Morgan Stanley
New York
|
-$43K |
| 5 |
Jane Street
New York
|
-$39.8K |
APRE Hedge Fund Activity: Q1 2026 in Review
22 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q1 2026, worth a combined $1.71M — up 18% from $1.45M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new APRE positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $507K. The largest seller was Murchinson, exiting entirely with an estimated $290K sold.
- 22 institutional investors held Aprea Therapeutics (APRE) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $1.71M of Aprea Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
- 7 funds opened new Aprea Therapeutics positions in Q1 2026 and 6 closed out, a net change of +1 holder.
- The largest Aprea Therapeutics buyer in Q1 2026 was AIGH Capital Management, an estimated $507K added.
- The largest Aprea Therapeutics seller in Q1 2026 was Murchinson, an estimated $290K sold.
Based on aggregated 13F filings for Q1 2026.